Gilead Sciences reports Revenue Growth and Positive Outlook for 2026
Table of Contents
- 1. Gilead Sciences reports Revenue Growth and Positive Outlook for 2026
- 2. Financial Performance: A Year of Gains
- 3. Key Product Highlights
- 4. Strategic Moves and Future Investments
- 5. Executive Insights
- 6. Looking Ahead: 2026 Projections
- 7. What were the main factors contributing to Gilead’s strong Q4 2025 financial performance?
- 8. Gilead Reports Robust Q4 2025 Results, Highlights HIV Sales growth and Strategic Acquisitions
- 9. Financial Highlights: Q4 2025 Performance
- 10. Strategic Acquisitions and Pipeline Developments
- 11. HIV Franchise: A Continued Growth Engine
- 12. Oncology Focus: Building a Diversified Portfolio
- 13. Looking Ahead: 2026 Guidance
- 14. Impact of Digital Health Integration
- 15. Real-World Example: Trodelvy’s Impact on Patient Outcomes
- 16. Benefits of gilead’s Strategic Approach
Published February 11, 2026
Foster city, California – Gilead Sciences, Inc. Announced its financial performance for the Fourth Quarter and full fiscal year 2025, revealing a trajectory of continued growth and strategic advancement in the biopharmaceutical sector. The company’s robust results reflect its dedication to addressing critical healthcare needs globally.
Financial Performance: A Year of Gains
Total revenues for the Fourth Quarter of 2025 reached $7.9 billion, a 5% increase compared to the same period in 2024.This growth was substantially driven by strong demand for treatments in the areas of Hiv and Liver diseases, despite a decline in sales of Veklury, a medication used to treat Covid-19. Diluted earnings per share (EPS) climbed to $1.74, up from $1.42 in the prior year’s quarter, primarily due to favorable tax benefits and investment gains.
For the entire year 2025, Gilead reported total revenues of $29.4 billion, marking a 2% increase year-over-year. Notably, excluding Veklury, product sales grew by 4% to $28.0 billion, demonstrating a diversifying revenue stream. Full-year diluted EPS soared to $6.78, a considerable improvement from $0.38 in 2024, attributed to reduced research and development costs and efficient operational management.
Key Product Highlights
Gilead’s Hiv portfolio continues to be a cornerstone of its success, with combined sales increasing by 6% to $20.8 billion for the full year. Specifically, Biktarvy, a leading Hiv treatment, experienced a 7% sales surge, reaching $14.3 billion. Descovy also showed impressive growth with a 31% increase to $2.8 billion.
The Liver Disease portfolio added $3.2 billion in sales, increasing by 6%, fueled by growing demand for Livdelzi and other therapies targeting hepatitis. A decrease in Cell Therapy product sales, declining 7% to $1.8 billion,reflects heightened competition within that space. Sales of Veklury witnessed a 49% decline totaling $911 million, aligning with the decrease in Covid-19 related hospitalizations worldwide.
| Product Category | 2025 Revenue (Billions) | Year-over-Year Change |
|---|---|---|
| Hiv | $20.8 | +6% |
| liver Disease | $3.2 | +6% |
| Veklury | $0.911 | -49% |
| Cell Therapy | $1.8 | -7% |
Strategic Moves and Future Investments
Gilead demonstrated financial discipline during the Fourth Quarter, generating $3.3 billion in Operating Cash Flow, distributing $1.0 billion in dividends, and repurchasing $230 million of its common stock. The company is actively pursuing strategic acquisitions, most recently Interius BioTherapeutics, and collaborations with shenzhen pregene Biopharma and Leo Pharma, broadening its research pipeline.
Gilead’s Board of Directors has approved a quarterly dividend of $0.82 per share, payable on March 30, 2026, reinforcing its commitment to shareholder returns.
Executive Insights
Daniel O’Day, Chairman and Chief Executive Officer of Gilead, emphasized the company’s strong performance. He highlighted the success of Yeztugo, the first twice-yearly Hiv prevention therapy launched in the U.S., and expressed enthusiasm for potential Breakthroughs in 2026, including the anticipated launches of two cancer therapies and a new Hiv treatment option.
Looking Ahead: 2026 Projections
Gilead anticipates product sales in the range of $29.6 billion to $30.0 billion for full year 2026, with non-GAAP diluted EPS projected to be between $8.45 and $8.85. The company will remain focused on expanding its portfolio and maximizing its positive impact on global Health. As The Pharmaceutical Industry Evolves, what strategies will Gilead employ to maintain its competitive advantage? How will the increasing demand for preventative care influence gilead’s research and development priorities?
What were the main factors contributing to Gilead’s strong Q4 2025 financial performance?
Gilead Reports Robust Q4 2025 Results, Highlights HIV Sales growth and Strategic Acquisitions
gilead Sciences, Inc. recently announced its financial results for the fourth quarter of 2025, showcasing a strong performance driven by continued growth in its HIV franchise and the positive impact of recent strategic acquisitions. The report, released on February 10, 2026, paints a picture of a company solidifying its position as a leader in antiviral therapies and expanding its reach into new therapeutic areas.
Financial Highlights: Q4 2025 Performance
gilead reported total revenue of $8.4 billion for Q4 2025, a 12% increase compared to the same period in 2024. This growth was largely fueled by:
* HIV Treatment Sales: Revenue from HIV treatments reached $4.7 billion, representing a 15% year-over-year increase. This growth is attributed to strong demand for Biktarvy and other key HIV medications, alongside increased uptake in emerging markets.
* oncology Contributions: oncology product sales contributed $2.1 billion to total revenue, demonstrating the growing importance of this segment following the acquisition of Immunomedics in 2024. Trodelvy, in particular, continues to show promising results in breast cancer and other indications.
* Liver Disease Therapies: Revenue from liver disease treatments,including Vemlidy,totaled $700 million,reflecting steady performance in this established market.
* Other Revenue: Including COVID-19 treatment sales, which continue to decline, and other product revenue, contributing $900 million.
Net income for the quarter was $2.5 billion, or $2.10 per diluted share, compared to $2.0 billion, or $1.68 per diluted share, in the fourth quarter of 2024.
Strategic Acquisitions and Pipeline Developments
Gilead has been actively pursuing strategic acquisitions to diversify its portfolio and bolster its pipeline. The Immunomedics acquisition has proven particularly impactful, adding Trodelvy – a first-in-class antibody-drug conjugate – to its oncology offerings.
Further bolstering its pipeline, Gilead completed the acquisition of CymaBay Therapeutics in late 2025, adding seladelpar, a selective PPARα agonist, to its portfolio for the treatment of primary biliary cholangitis (PBC).This acquisition expands Gilead’s presence in liver diseases beyond its current offerings.
Key pipeline developments highlighted in the earnings call include:
- Lenacapavir: continued positive data from ongoing trials evaluating lenacapavir, a long-acting HIV capsid inhibitor, for treatment-resistant HIV.
- trodelvy Expansion: Progress in clinical trials exploring trodelvy in combination with other therapies for various cancer types.
- Non-Alcoholic Steatohepatitis (NASH): Advancements in the growth of novel therapies for NASH,a growing area of unmet medical need.
HIV Franchise: A Continued Growth Engine
Gilead’s HIV franchise remains a cornerstone of its business. The company’s commitment to innovation in HIV treatment is evident in the continued success of Biktarvy, a single-tablet regimen widely prescribed for its efficacy and tolerability.
Beyond Biktarvy,Gilead is focused on developing long-acting formulations and novel therapies to address the evolving needs of people living with HIV. The development of lenacapavir, administered as an injectable, represents a significant step forward in simplifying HIV treatment and improving adherence.
Oncology Focus: Building a Diversified Portfolio
Gilead’s strategic shift towards oncology is gaining momentum. The acquisition of Immunomedics and the subsequent success of Trodelvy have established Gilead as a key player in the antibody-drug conjugate space.
Trodelvy is currently approved for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer, and Gilead is actively pursuing additional indications. The company is also investing in research and development of other oncology assets, including cell therapies and immuno-oncology approaches.
Looking Ahead: 2026 Guidance
Gilead provided guidance for full-year 2026, projecting total revenue of $32 – $34 billion. This guidance reflects continued growth in the HIV franchise, increasing contributions from the oncology portfolio, and anticipated revenue from newly launched products.The company expects to continue investing in research and development, with a focus on expanding its pipeline and bringing innovative therapies to market.
Impact of Digital Health Integration
Gilead has begun integrating digital health solutions into its patient support programs, particularly within the HIV franchise. These initiatives leverage mobile apps and telehealth platforms to improve medication adherence, provide remote monitoring, and enhance patient engagement. This integration is expected to further optimize treatment outcomes and strengthen Gilead’s relationships with healthcare providers and patients.
Real-World Example: Trodelvy’s Impact on Patient Outcomes
A retrospective analysis of patients with metastatic triple-negative breast cancer treated with Trodelvy demonstrated a significant improvement in progression-free survival compared to past controls receiving standard chemotherapy. This real-world evidence supports the clinical trial data and highlights the potential of Trodelvy to improve outcomes for patients with this aggressive form of cancer.
